To determine if radiomic features derived from MRI scans of cirrhotic patients can predict disease severity, specifically as approximated by MELD score and presence of decompensation.
Key Findings:
Cirrhosis is a significant global health issue with high mortality rates, necessitating improved assessment methods.
MELD scoring system is used for stratifying liver transplant candidates based on estimated mortality, highlighting the need for accurate prognostic tools.
Radiomic feature analysis has potential to serve as a noninvasive prognostic factor for liver disease severity, which could transform patient management.
Interpretation:
Radiomic features may enhance the assessment of liver disease severity, potentially improving transplant prioritization and clinical decision-making beyond traditional MELD scores.
Limitations:
Study limited to a single center with specific MRI protocols, which may affect generalizability and introduce selection bias.
Challenges in MRI-based radiomic feature extraction due to signal normalization and acquisition artifacts, impacting feature reliability.
Conclusion:
This study aims to establish a radiomic signature for cirrhosis severity assessment, potentially improving patient management and transplant prioritization, thereby enhancing clinical outcomes.
In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.
